Wantai Biopharm’s Cecolin 9 HPV Vaccine Approved by China’s NMPA

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its 9-valent human papillomavirus (HPV) vaccine (Escherichia coli), Cecolin 9, has received marketing approval from China’s National Medical Products Administration (NMPA). The vaccine is indicated for females aged 9-45 years. For ages 9-17, the dosing regimen is a 2-dose schedule (at 0 and 6 months), while for ages 18-45, it is a 3-dose schedule (at 0, 1, and 6 months).

Comparison with Existing Vaccines
Prior to this approval, Merck’s Gardasil 9 was the only globally available 9-valent HPV vaccine. Gardasil 9 was first approved in China in 2018. Its indication was later expanded to cover females aged 9-45 under the following regimens: a 2-dose schedule (at 0 and 6-12 months) for ages 9-14 and a 3-dose schedule (at 0, 2, and 6 months) for ages 15-45. In April 2025, Gardasil 9 also gained approval in China for males aged 16-26.-Fineline Info & Tech